Clinical control study of recombinant human growth hormone in the treatment of ulcerative colitis

doi:10.3877/cma.j.issn.2095-3224.2016.06.005

Abstract

Abstract:

Objective

To study the effect of recombinant human growth hormone (r-hGH) in the treatment of ulcerative colitis.

Methods

Fifty-five patients with ulcerative colitis were collected from 2011 to 2016 in Second People′s Hospital of Huai′an, and were randomly grouped into research group (30 cases) and control group (25 cases). Two groups of patients are comparable with age, occupation, duration, colonoscopy lesions scope and Mayo score (t=0.163, P=0.163). Two groups of patients were under a total of 14 days treatment. The research group was added with subcutaneous injection of recombinant human growth hormone, 4 iu qd, 14 days. Two groups of patients were analyzed the Mayo score and serum tumor necrosis factor alpha (TNF alpha), interleukin 1 beta (IL-1 beta) before and after treatment respectively.

Results

In research group, the Mayo score (t=15.425, P<0.001) and TNF alpha (t=7.080, P<0.001) were of highly significant statistical difference before and after treatment, there was no significant statistical difference in IL-1 beta changes (t=0.402, P=0.402). In the control group, the Mayo score was of significant statistical difference (t=9.165, P=9.165) before and after treatment, the TNF alpha beta (t=1.472, P=0.154), IL-1 (t=0.941, P=0.356) was of no significant statistical difference.

Conclusion

The recombinant human growth hormone can effectively reduce the blood level of TNF alpha in ulcerative colitis patients, promoting restoration of large intestine mucosa in patients with ulcerative colitis.

Key words: Colon, Therapy, Recombinant human growth hormone, Ulcerative colitis, Controlled study

Jingjing Wan, Dongsheng Xu, Bingyin Yang, Xinggang Ma. Clinical control study of recombinant human growth hormone in the treatment of ulcerative colitis[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(06): 480-483.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.06.005

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I06/480

Figures/Tables 3

References 19

[1]	何小华. 炎症性肠病发病的相关免疫机制[J]. 南昌大学学报(医学版), 2011, 51(10): 93-96.
[2]	Pichai MV,Ferguson LR. Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases[J]. World J Gastroenterol, 2012, 18(23): 2895-2901.
[3]	江学良. 溃疡性结肠炎现代治疗诊疗手册[M]. 北京: 中国医药科技出版社, 2006: 81-90.
[4]	Ding HG,Shan J,Zhang B, et al. Combined human growth hormone and lactulose for prevention and treatment of multiple organ dysfunction in patients with severe chronic hepatitis B[J]. World J Gastroenterol, 2005, 11(19): 2981-2983.
[5]	郭光华,蔡晨,李国辉, 等. 肠内免疫营养联合重组人生长激素对烫伤大鼠的治疗作用[J]. 中国危重病急救医学, 2006, 18(1): 42-45.
[6]	王兴鹏,王冰娴,吴建新, 等. 生长激素对实验性急性坏死性胰腺炎肠道细菌移居的影响[J]. 中华消化杂志, 2000, 20(3): 171-174.
[7]	Scopa CD,Koureleas S,Tsamandas AC, et al. Beneficial effects of growth hormone and insulin-like growth factor 1 on intestinal bacterial translocation, endotoxemia, and apoptosis in experimentally jaundiced rats[J]. J Am Coll Surg, 2000, 190(4): 423-431.
[8]	Yang ZW,Li JG,Mao XG, et al. Effects of recombinant human growth hormone on intestinal translocation of bacteria and endotoxin in rats with obstructive jaundice[J]. Hepatobiliary Pancreat Dis Int, 2005, 4(3): 445-449.
[9]	黄英,王树人,应明英, 等. 重组人生长激素对败血症大鼠的实验治疗[J]. 中国病理生理杂志, 2003, 19(9): 1253-1256.
[10]	Han X,Sosnowska D,Bonkowski EL, et al. Growth Hormone Inhibits Signal Transducer and Activator of Transcription 3 Activation and Reduces Disease Activity in Murine Colitis[J]. Gastroenterology, 2005, 129(1): 185-203.
[11]	Kara E,Sungurtekin H,Sungurtekin U, et al. The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats. An experimental study[J]. Inflamm Bowel Dis, 2004, 10(2): 112-115.
[12]	Coburn L A,Gong X,Singh K, et al. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis[J]. Plos One, 2012, 7(3): e33546.
[13]	秦爽,贺育兰,杨静, 等. 重组人生长激素对内毒素诱导人巨噬细胞产生TNF-α、IL-1β含量的影响[J]. 中国感染控制杂志, 2008, 7(1): 9-11.
[14]	Goh KL,Xiao SD. Inflammatory bowel disease: A survey of the epidemiology in Asia[J]. J Dig Dis, 2009, 10(1): 1-6.
[15]	尹岸民. 溃疡性结肠炎患者血浆炎性反应细胞因子水平的变化[J]. 吉林医学, 2011, 32(27): 5682-5682.
[16]	Owczarek D,Cibor D,Głowacki MK, et al. TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn′s disease and ulcerative colitis[J]. Pol Arch Med Wewn, 2012, 122(12): 616-623.
[17]	Coccia M,Harrison OJ,Schiering C, et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4^＋Th17 cells[J]. J Exp Med, 2012, 209(9): 1595-1609.
[18]	朱向东,曹燕飞,王燕, 等. 溃疡性结肠炎大鼠血清白细胞介素-1β、肿瘤坏死因子-α、白细胞介素-4动态表达规律[J]. 中国老年学杂志, 2015, 35(2): 410-412.
[19]	唐月华,王小平. 溃疡性结肠炎患者血清IL-1β和IL-18的表达及临床意义[J]. 河北医药, 2015, 37(10): 1534-1535.

组别	例数	治疗前	治疗后
研究组	30	8.1±2.5	5.5±1.9
对照组	25	8.0±2.3	6.6±1.9
t值	?	0.163	-2.007
P值	?	0.871	P<0.05

组别	例数	治疗前	治疗后
研究组	30	8.1±2.5	5.5±1.9
对照组	25	8.0±2.3	6.6±1.9
t值	?	0.163	-2.007
P值	?	0.871	P<0.05

组别	例数	治疗前	治疗后
研究组	30	15.7±5.9	10.9±3.2
对照组	25	15.5±2.7	15.3±2.2
t值	?	0.183	-5.667
P值	?	0.855	<0.001

组别	例数	治疗前	治疗后
研究组	30	15.7±5.9	10.9±3.2
对照组	25	15.5±2.7	15.3±2.2
t值	?	0.183	-5.667
P值	?	0.855	<0.001

组别	例数	治疗前	治疗后
研究组	30	5.4±2.7	5.4±2.7
对照组	25	5.2±0.7	5.0±0.8
t值	?	0.556	0.723
P值	?	0.580	0.473

Please choose a citation manager

Content to export